BioSpace News Archive

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will participate in the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022 beginning at 2:30 pm ET.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that it has completed enrollment and dosing in Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans.

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, announced today that the company’s CEO, Alon Ben-Noon, has been invited to present at the 2022 Virtual Growth Conference.

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.

BostonGene Corporation and Thomas Jefferson University announced the online publication of the manuscript, “Tadalafil enhances immune response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma” in the American Association for Cancer Research journal Clinical Cancer Research.

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive product candidates for pain management as well as PTSD, CNS disorders and anti-viral indications, expanded its exclusive license agreement for AnQlar™ with Nanomerics Ltd., providing Virpax with the worldwide rights for development and commercialization.

Co-Diagnostics, Inc. announced that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock.

Mablink Bioscience S.A.S. (“Mablink”), a biotechnology company developing a pipeline of antibody-drug conjugates (ADCs) based on its proprietary PSARlink™ drug-linker technology to treat cancers with high unmet needs, today announced the appointment of its Head of Preclinical Research and Development: Lenka Kyrych Sadilkova, PhD.

Asahi Kasei, a diversified Japanese multinational company, has formed a strategic partnership with Genomatica, Inc., regarding hexamethylenediamine based on biomass-derived raw material.

The American Urological Association is proud to launch the AUA Institute for Leadership & Business, a new initiative dedicated to providing education, training and resources to support leadership development and business acumen within the urology community.